← Issue №13/ week of Sep 27, 2026/Hepatology

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology guideline · Sep 24, 2026 · Gut · IF 24.6

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies.

Guideline / reviewhepatocellular carcinomaguideline
Clinical takeawayNo clinical action yet: expert consensus on trial design for HCC systemic therapy in earlier disease stages, not yet tested in practice.
What it foundConsensus statements defined for trial design in HCC systemic therapy, including high-risk recurrence criteria (patients at highest risk of recurrence, with 2-year event-free survival as primary outcome) and comparator arms (systemic therapy for patients with larger tumour burden and locally advanced disease).
ContextRefines trial design for HCC systemic therapy in earlier stages, addressing heterogeneity and defining endpoints for neoadjuvant/perioperative (2-year event-free survival) and combination therapy trials (progression-free survival and overall survival).
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Yarchoan M … Singal AG · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues